Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that the Company has issued its October 2019 Corporate Update Letter. The Letter highlights the progress of the Company's product candidates Mino-Lok®, Mino-Wrap™, and Halo-Lido, along with details on its strategic goals to develop breakthrough technologies to improve and enhance the lives of patients.

Recent Company Highlights include:

• Closing on a recent $7 million capital raise to advance ongoing research
• A recent modification to the primary endpoint of the pivotal Phase III trial for Mino-Lok that substantially reduced the required trial sample size from 700 to approximately 144 subjects, significantly reducing the trial's expense and accelerating its completion
• An expanded relationship with MD Anderson Cancer Center for a worldwide license for Mino-Wrap and the preparation for a pre-IND meeting with the FDA
• Reformulating the topical formulation (now Halo-Lido) for the treatment of hemorrhoids based on results from an initial Phase II study. A toxicology study will be initiated by year-end ahead of an expanded Phase II study to start in 2020
• Other corporate initiatives that include industry events and investor outreach

To view the Company's Corporate Update Letter in its entirety, please visit: https://www.citiuspharma.com/wp-content/uploads/2019/11/CTXR-ShareholderLetter-Nov2019.pdf

About Citius Pharmaceuticals, Inc.

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care, and unique prescription products that use innovative, patented, or proprietary formulations of previously-approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com.